CureMatch

08/21/2025

CureMatch considers all possible novel 2- and 3- drug combinations as well as known ones of the 300 or so cancer drugs, as this means millions of possibilities (>4.5M), and with 5+ markers per molecular profile of each cancer, there are TRILLIONS of possible patterns. To generate and then narrow down to only top most fitting options…navigating this complexity is the problem we solve.

05/23/2025

Our ASCO paper is now published! This was in collaboration with one of the largest Clincial Research Organizations, , TransThera, MD Anderson & Wisconsin College of Medicine.

The unique scoring approach is first of its kind, and this work marks a huge advance in precision oncology taking molecular matching to the next level of validity.

https://www.linkedin.com/posts/curematch_use-of-an-in-silico-clinical-trial-intelligence-activity-7331462868925677568-psPN?utm_medium=ios_app&rcm=ACoAAAFUWAEBt6BacDgB377mB-ABD_NvDLokZOo&utm_source=social_share_send&utm_campaign=gmail

CureMatch results predicting clinical trial outcomes now published and live on the ASCO website:

https://lnkd.in/dpTSEvBs

We are proud to have delivered valuable insights in collaboration with TransThera Biosciences, Inc. on their Phase II clinical trial data of tinengotinib - a multikinase inhibitor targeting specific FGF family receptors.

CureMatch scores for 37 cholangiocarcinoma patients were produced using genomic profiling data (next-gen sequencing, ), as well as the drug targeting profile as inputs. Score thresholds were also determined.

In these molecular analyses CureMatch was BLINDED as to clinical outcomes.

When the outcomes were revealed, our score was predictive with incredible accuracy (p

This link will take you to a page that’s not on LinkedIn

03/09/2025

02/18/2025

A great quote from our co-founder Dr. Razelle Kurzrock highlighting the CureMatch value add:

“The average tumor has 5 genomic alterations, and if there are about 700 cancer genes, that means greater than one trillion patterns.“

01/30/2025

Webinar moderated by Director at The Sheba Medical Center at Tel Hashomer on CureMatch. Our Co-founder Dr. Razelle Kurzrock discussed how we assist in personalized treatment, match molecular markers to enable tailored combos to address as many biomarkers as possible w/each patient’s cancer:

This link will take you to a page that’s not on LinkedIn

01/23/2025

What we shared on the The White House post on this topic:

We are excited as to the attention being given to the convergence of & the fight against . At CureMatch we are doing this already with EXISTING drugs available & helping get patients matched to trials to accelerate the process of clearance.

We are like a guidance system. CureMatch does not do the NGS lab work (just like GPS tools do not build roads).

However we address the cancer complexity problem. The average tumor has 5 genomic alterations. If there are about 700 cancer genes, that means greater than one trillion patterns. Moreover, if there are about 300 drugs in oncology, there are approximately 45,000 two-drug combinations and about 4.5 million three-drug combinations. These numbers illustrate the need of a "GPS" guidance system since this is beyond human cognition. That is what we do with NGS from any lab, plus transcriptomics, protein alterations etc.

01/17/2025

During a packed show, the American country superstar Garth Brooks halted his performance mid-song when he saw a fan holding a sign that said, "Chemo this morning. Garth tonight. Enjoying the dance”. Her sign caught Garth off-guard but what he did when he saw her sign made this video a viral hit and captured the hearts of people all around the world. Watch video on The Music Man in comments below 👇

During a packed show, the American country superstar Garth Brooks halted his performance mid-song when he saw a fan holding a sign that said, "Chemo this morning. Garth tonight. Enjoying the dance”. Her sign caught Garth off-guard but what he did when he saw her sign made this video a viral hit and captured the hearts of people all around the world. Watch video on The Music Man in comments below 👇

01/17/2025

lab work + CureMatch

Guardant Health Tempus Labs Caris Life Sciences BostonGene Breastlink NeoGenomics Laboratories Labcorp

www.curematchdirect.com

lab work + CureMatch

Guardant Health Tempus Labs BostonGene Breastlink Caris Life Sciences NeoGenomics Laboratories Labcorp

www.curematchdirect.com

01/08/2025

We determine “molecular eligibility” of a to by evaluating NGS profiles of patients and matching them with clinical trials that have highly ranked drugs or combinations for each patient’s cancer. The assessment of impact of a tested in the clinical trial on the patient’s molecular profile is based on the number and types of clinically significant in the molecular profile and their interaction between each other and the drug(s) of the trial therapy.

01/07/2025

Tissue-agnostic targeted treatment based on molecular profile of each individual patient, this is what we do CureMatch with the lab NGS from any lab ( Guardant Health Tempus Labs Caris Life Sciences NeoGenomics Laboratories BostonGene) as our input. We can also match patients for clinical trials based on the CureMatch report. Novartis Pfizer AstraZeneca Biogen AbbVie Sanofi

12/14/2024

CureMatch can help accelerate focused . A significant amount of time for clinical trials is spent recruiting patients, and many trials do not recruit the required number of people. Our KRR (Knowledge, Representation & Reasoning) AI can help in designing trial criteria & identifying suitable patients for trials based on their lab work from any lab.

12/05/2024

At CureMatch we excel at qualifying & quantifying therapy options based on each patient's molecular profile, so as many cancer drivers can be targeted by as few matched drugs as possible, while warning of potentially harmful treatments. Multiple oncogenic alterations with known actionability present a complex problem that we solve with our KRR . Across different cancer types, technologies & in different countries facing the same cancer complexity challenge hampering precision medicine adoption in many clinical communities. Syneos Health NeoGenomics Laboratories OncoDaily